Abstract: A device for estimating breast implant volume is provided, which may include an input interface and a processing circuit. A numerical value may be inputted in to the input interface. The processing circuit may calculate the estimation value of breast implant volume according to a linear model and the numerical value. The processing circuit may multiply the numerical value by a coefficient to generate a product, and add a constant to the product to generate the estimation value of breast implant volume, wherein the numerical value may be a breast sample weight or a breast size.

Abstract: A system for assessing extubation includes a respiratory assistance device, an artificial intelligence platform, and a hospital information system. The respiratory assistance device is adapted to communicate with a trachea of a patient. The artificial intelligence platform includes a prediction module. A method for assessing extubation includes the following steps. Measured values of respiratory parameters of the patient are recorded by the respiratory assistance device. The recorded times and the measured values of the respiratory parameters corresponding to each of the recording times are transmitted to the artificial intelligence platform. The prediction module analyzes the measured values of respiratory parameters within a predetermined time period according to a prediction model to generate a prediction result. The prediction result is transmitted to the hospital information system and is recorded into a medical record of the patient.

Abstract: An oral rehabilitation device for rehabilitating the oral cavity of a user includes a device body, a first activating member, an upper-jaw member, a lower-jaw member, and a processing unit. The first activating member is disposed on an end of the device body. The upper-jaw member and the lower-jaw member are connected to the same end of the device body and are for contacting an upper jaw and lower jaw of the user, respectively. The processing unit is coupled to the first activating member and is used to control the first activating member to drive one of the upper-jaw member and the lower jaw member to open or close relative to the other of the upper-jaw member and the lower-jaw member, such that the upper jaw and the lower jaw can be rehabilitated. The present invention further discloses a medical treatment system to which the oral rehabilitation device is linked.

Abstract: The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.

Abstract: A system for assessing extubation includes a respiratory assistance device, an artificial intelligence platform, and a hospital information system. The respiratory assistance device is adapted to communicate with a trachea of a patient. The artificial intelligence platform includes a prediction module. A method for assessing extubation includes the following steps. Measured values of respiratory parameters of the patient are recorded by the respiratory assistance device. The recorded times and the measured values of the respiratory parameters corresponding to each of the recording times are transmitted to the artificial intelligence platform. The prediction module analyzes the measured values of respiratory parameters within a predetermined time period according to a prediction model to generate a prediction result. The prediction result is transmitted to the hospital information system and is recorded into a medical record of the patient.

Abstract: A purifying device including a container, at least one cover, a sensing assembly and an ultraviolet source is provided. The container has a containing space, wherein the containing space is adapted to contain a liquid. The cover is adapted to be connected to the container to cover the containing space. The sensing assembly is disposed on the cover, wherein the sensing assembly is adapted to sense a usage state of the cover. The ultraviolet source is disposed on the cover and is adapted to generate an ultraviolet emitted to outside of the cover, wherein the ultraviolet source is turned on or turned off according the usage state of the cover.

Abstract: A mouth-opening training device includes a water-filled bag having a zigzag edge or a sawtooth edge. By increasing or decreasing the amount of water located inside the water-filled bag to alter the total thickness of the water-filled bag, the device can accommodate different thickness of occlusion of teeth of a patient. The device can make a further improvement on layers of flavor in occlusion of the teeth. The device can further include a plurality of pivotable plate-shaped objects connected or coupled to the water-filled bag. The plate-shaped objects can provide different thickness combinations and further meet the user demands on thickness of occlusion of the teeth.

Abstract: A positioning system by visible light includes at least one luminaire, at least one positioning transceiver and a server. The luminaire is disposed at a specific position and has a first identification code, and emits the first identification code in a selected signal form. Each positioning transceiver has a second identification code, and further includes a receiving device and a wireless transceiver. The receiving device movably receives the first identification and demodulates the first identification code. The wireless transceiver transmits the first and the second identification codes to a receiving terminal. The server is coupled to the at least one positioning transceiver via the receiving terminal, and obtains the first and the second identification codes so as to position the at least one positioning transceiver in a space defined by the at least one luminaire.

Abstract: The present invention provides a pharmaceutical composition for treating a patient suffering from or predisposed to hyperphosphatemia, which contains Mg—Fe—Cl HCln. In one embodiment, the Mg—Fe—Cl HCln is shown in formula (I). The phosphorus uptaking capacity of the pharmaceutical composition is greater than 100 ppm/(g/L). The present invention further provides a method for treating a patient suffering from or predisposed to hyperphosphatemia by using said pharmaceutical composition. The present invention further provides a method of manufacturing the pharmaceutical composition.

Abstract: A positioning system by visible light includes at least one luminaire, at least one positioning transceiver and a server. The luminaire is disposed at a specific position and has a first identification code, and emits the first identification code in a selected signal form. Each positioning transceiver has a second identification code, and further includes a receiving device and a wireless transceiver. The receiving device movably receives the first identification and demodulates the first identification code. The wireless transceiver transmits the first and the second identification codes to a receiving terminal. The server is coupled to the at least one positioning transceiver via the receiving terminal, and obtains the first and the second identification codes so as to position the at least one positioning transceiver in a space defined by the at least one luminaire.

Abstract: A purifying device including a container, at least one cover, a sensing assembly and an ultraviolet source is provided. The container has a containing space, wherein the containing space is adapted to contain a liquid. The cover is adapted to be connected to the container to cover the containing space. The sensing assembly is disposed on the cover, wherein the sensing assembly is adapted to sense a usage state of the cover. The ultraviolet source is disposed on the cover and is adapted to generate an ultraviolet emitted to outside of the cover, wherein the ultraviolet source is turned on or turned off according the usage state of the cover.

Abstract: A positioning system by visible light includes at least one luminaire, at least one positioning transceiver and a server. The luminaire is disposed at a specific position and has a first identification code, and emits the first identification code in a selected signal form. Each positioning transceiver has a second identification code, and further includes a receiving device and a wireless transceiver. The receiving device movably receives the first identification and demodulates the first identification code. The wireless transceiver transmits the first and the second identification codes to a receiving terminal. The server is coupled to the at least one positioning transceiver via the receiving terminal, and obtains the first and the second identification codes so as to position the at least one positioning transceiver in a space defined by the at least one luminaire.

Abstract: A positioning system by visible light includes at least one luminaire, at least one positioning transceiver and a server. The luminaire is disposed at a specific position and has a first identification code, and emits the first identification code in a selected signal form. Each positioning transceiver has a second identification code, and further includes a receiving device and a wireless transceiver. The receiving device movably receives the first identification and demodulates the first identification code. The wireless transceiver transmits the first and the second identification codes to a receiving terminal. The server is coupled to the at least one positioning transceiver via the receiving terminal, and obtains the first and the second identification codes so as to position the at least one positioning transceiver in a space defined by the at least one luminaire.

Abstract: An object location guiding device and an operation method thereof are provided. The object location guiding device includes a processor, a controller and a guiding element array. Guiding elements of the guiding element array are disposed at different positions in a field so as to point to storage positions of different objects in the field. The processor converts the object data on an object list into storage-position information. The controller receives the storage-position information from the processor, converts the storage-position information into a first axis position code and a second axis position code, and drives the guiding element array by using the first axis position code and the second axis position code, so as to allow at least one corresponding guiding element of the guiding elements to point to a storage position of a corresponding object in the field.

Abstract: A nasogastric tube includes a connector. The connector has a first connection end, a second connection end and a flow channel formed through the connector. The first connection end is connected to a first tube, and the second connection end has a positioning sleeve formed thereon. The positioning sleeve has a connection part extended from the flow channel and jointing with an assembling part of the second tube. The first tube of nasogastric tube of the present invention can be inserted to a stomach from a nasal cavity, and then the connector is placed in the nasal cavity, and the positioning sleeve is fixed in the nostril. The second tube can be detached from the connector when not being used.

Abstract: The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.

Abstract: The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.

Abstract: The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.

Abstract: A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking ; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provide a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker.

Abstract: An handheld accessory system for an ultrasonic equipment and an inspection method applicable to the accessory system. The accessory system includes a force detector and a positioning device attached to a hand-held ultrasonic probe, and a signal processing device. A user may apply the ultrasonic probe to the target tumor with a certain compression depth. A force compensation module in the signal processing device allows to make compensation due to unsteady compression depth, thereby providing for the operation of transverse palpation to detect the stiffness ratio and mobility of a target relative to its surrounding tissues, and being therefore specifically suitable for diagnosing breast tumors, as benign or malignant.